Enhanced delivery of rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 66 A, Issue 12, 2011, Pages 1274-1285

  Cho, Kyung Hyun ^a  

^a Yeungnam University   (South Korea)

Author keywords

apoA I; High density lipoprotein; Rapamycin; Rejuvenation; V156K

Indexed keywords

DANIO RERIO; MAMMALIA;

ACETYL LOW DENSITY LIPOPROTEIN; ACETYL-LDL; ANTIOXIDANT; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN; RAPAMYCIN; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL; ARTICLE; ATHEROSCLEROSIS; CELL AGING; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; FIN (ORGAN); GENETICS; HUMAN; MACROPHAGE; METABOLISM; PHYSIOLOGY; REGENERATION; SOLUBILITY; ZEBRA FISH;

AMINO ACID SUBSTITUTION; ANIMAL FINS; ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CELL AGING; CELL LINE; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; RECOMBINANT PROTEINS; REGENERATION; SIROLIMUS; SOLUBILITY; ZEBRAFISH;

EID: 81055147571     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glr169     Document Type: Article

References (43)

1. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392-395.
2. Flechner SM. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc. 2008;40:S25-S28.
3. Ciuffreda L, Di Sanza C, Incani UC, et al. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010;10:484-495.
4. Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122:52-61.
5. Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit. 2001;23:559-586. (Pubitemid 32912281)
6. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-772. (Pubitemid 39390578)
7. Patel S, Di Bartolo BA, Nakhla S, et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis. 2010;212:392-397.
8. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116:87-98.
9. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642-1648.
10. Newton RS, Krause BR. HDL therapy for the acute treatment of atherosclerosis. Atheroscler Suppl. 2002;3:31-38. (Pubitemid 38234484)
11. Tardif JC, Heinonen T, Noble S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep. 2009;11:58-63.
12. Han JM, Jeong TS, Lee WS, et al. Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J Lipid Res. 2005;46:589-596.
13. Cho KH, Park SH, Han JM, et al. ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities. Eur J Clin Invest. 2006;36:875-882. (Pubitemid 44707087)
14. Cho KH, Kim JR. A reconstituted high-density lipoprotein containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation. Exp Mol Med. 2009;41:417-428.
15. Park KH, Yun CO, Kwon OJ, et al. Enhanced delivery of an adenovirus, using proteoliposomes containing WT or V156K apolipoproteinA-I and dimyristoylphosphatidylcholine. Hum Gene Ther. 2010;21:579-587.
16. Lacko AG, Nair M, Paranjape S, et al. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002;22:2045-2049. (Pubitemid 34857021)
17. Oda MN, Hargreaves PL, Beckstead JA, et al. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res. 2006;47:260-267. (Pubitemid 43276912)
18. Bijsterbosch MK, van de Bilt H, van Berkel TJ. Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem Pharmacol. 1996;52:113-121. (Pubitemid 26199113)
19. Cho KH. Synthesis of reconstituted high-density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL. Mol Cells. 2009;27:291-297.
20. Staros JV. N-hydroxysulfosuccinimide active esters: bis(N- hydroxysulfosuccinimide) esters of two dicarboxylic acids are hydrophilic, membrane-impermeant, protein cross-linkers. Biochemistry. 1982;21:3950-3955.
21. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70-76.
22. Park KH, Shin DG, Kim JR, et al. Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity. J Gerontol A Biol Sci Med Sci. 2010;65:600-610.
23. Esterbauer H, Striegl G, Puhl H, et al. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67-75. (Pubitemid 19109796)
24. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res. 1968;9:693-700.
25. Fraenkel-Conrat H. Methods for investigating the essential groups for enzyme activity. Meth Enzymol. 1957;4:247-269.
26. Park KH, Jang W, Kim KY, et al. Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun. 2010;392:295-300.
27. Park KH, Cho KH. High-density lipoprotein (HDL) from elderly and reconstituted HDL containing glycated apolipoproteins A-I share proatherosclerotic and prosenescent properties with increased cholesterol influx. J Gerontol A Biol Sci Med Sci. 2011;66A:511-520.
28. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995;92:9363-9367.
29. Owusu-Ansah E, Yavari A, Mandal S, et al. Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nat Genet. 2008;4:356-361. (Pubitemid 351311760)
30. Olsen AS, Sarras MP Jr, Intine RV. Limb regeneration is impaired in an adult zebrafish model of diabetes mellitus. Wound Repair Regen. 2010;18:532-542.
31. Wills AA, Kidd AR 3rd, Lepilina A, et al. Fgfs control homeostatic regeneration in adult zebrafish fins. Development. 2008;135:3063-3070.
32. Fuhrman B, Judith O, Keidar S, et al. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic Biol Med. 1997;23:34-46. (Pubitemid 27217006)
33. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003;290:2030-2040. (Pubitemid 37430586)
34. Sanders AE, Wang C, Katz M, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA. 2010;303:150-158.
35. Tall AR. Plasma lipid transfer proteins. J Lipid Res. 1986;27:361-367.
36. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164.
37. Libby P. Fat fuels the flame triglyceride-rich lipoproteins and arterial inflammation. Circ Res. 2007;100:299-301.
38. Cho KH, Shin DG, Baek SH, et al. Myocardial infarction patients showed altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp Mol Med. 2009;41:67-76.
39. Quintão EC, Cazita PM. Lipid transfer proteins: past, present and perspectives. Atherosclerosis. 2010;209:1-9.
40. Kolovou G, Stamatelatou M, Anagnostopoulou K, et al. Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome. Open Cardiovasc Med J. 2010;4:14-19.
41. Cellini E, Nacmias B, Olivieri F, et al. Cholesteryl ester transfer protein (CETP) I405V polymorphism and longevity in Italian centenarians. Mech Ageing Dev. 2005;126:826-828. (Pubitemid 40693306)
42. Arai Y, Hirose N. Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb. 2004;11:246-252.
43. Nikkilä M, Heikkinen J. High-density lipoprotein cholesterol and longevity. Age Ageing. 1990;19:119-124. (Pubitemid 20100153)